Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
T ype 2 diabetes is a complex meta-bolic disorder characterized byhyperglycemia arising from a com-bination of insufficient insulin secretion together with resistance to insulin action. The incidence and prevalence of type 2 diabetes are rising steadily, fuelled in part by a concomitant increase in the world-wide rates of obesity. As longitudinal studies of type 2 diabetes provide evi-dence linking improved glycemic control with a reduction in the rates of diabetes-associated complications, there is consid-erable interest in the therapy of type 2 diabetes (Fig. 1), with a focus on the de-velopment and use of new agents that ex-hibit improved efficacy and safety relative
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, it was implicated that GLP-1 analogue therapy increased the risk of acute pancreatitis, but subsequent studies using larger cohorts did not confirm this finding.8,267”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [267]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 4×
“Moreover, both exenatide and liraglutide reduce blood pressure, body weight, and plasma lipid profiles in subjects with type 2 diabetes (13), raising the hope that longterm treatment with these agents may reduce the incidence of cardiovascular events.”
BackgroundInfluentialSelf-citationLaboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Self-citationOral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Intriguingly, the GLP-1 metabolite, GLP-1 (9–36), also exerts cardioprotective actions in preclinical studies through mechanisms independent of the known GLP-1R (14); hence, ongoing research is directed at understanding the complexity of incretin biology in the cardiovascular system and the potential for incretin-base…”
BackgroundSelf-citationNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901
Research works printed but not linked: 2
- Horner, SEER Cancer Statistics Review, 1975–2006 [Internet], 2009
- Parola, 2009, FDA Advisory Committee Nonclinical Briefing Document, NDA, 22
Cited by
Items 101–200 of 321
Hompesch, M., Jones‐Leone, A., Carr, M. C., Matthews, J., Zhi, H., Young, M., Morrow, L., & Reinhardt, R. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12398 · Cited by 31
Piro, S., Mascali, L. G., Urbano, F., Filippello, A., Malaguarnera, R., Calanna, S., Rabuazzo, A. M., & Purrello, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090093 · Cited by 36
Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes
Unger, J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0404-x · Cited by 30
Glucagon-like peptide-1 receptor agonist stimulates mitochondrial bioenergetics in human adipocytes
Góralska, J., Śliwa, A., Gruca, A., Raźny, U., Chojnacka, M., Polus, A., Solnica, B., & Malczewska-Malec, M. (2017) · Acta Biochimica Polonica · doi:10.18388/abp.2017_1634 · Cited by 34
Kuritzky, L., Umpierrez, G., Ekoé, J., Mancillas-Adame, L., & Lando, L. (2014) · Postgraduate medicine · doi:10.3810/pgm.2014.10.2821 · Cited by 29
Dunkley, A. J., Fitzpatrick, C., Gray, L. J., Waheed, G., Heller, S. R., Frier, B. M., Davies, M. J., Khunti, K., & on behalf of the Primary Care Diabetes Society (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13690 · Cited by 29
Incretin Therapy – Present and Future
Garber, A. J. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.307 · Cited by 31
Yang, J., Lin, Y.-T., Chen, W., Yang, Y., Sun, S., & Chen, S. (2020) · Biology · doi:10.3390/biology9110348 · Cited by 32
Haluzík, M., Kratochvílová, H., Haluzíková, D., & Mráz, M. (2018) · Journal of Endocrinology · doi:10.1530/joe-17-0438 · Cited by 32
Natural products with potential hypoglycemic activity in T2DM: 2019–2023
Fei, Z., Xu, Y., Zhang, G., Yang, L., Li, H., & Chen, L. (2024) · Phytochemistry · doi:10.1016/j.phytochem.2024.114130 · Cited by 34
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 30
Addy, C., Tatosian, D. A., Glasgow, X. S., Gendrano, I. N., Kauh, E. A., Martucci, A., Johnson‐Levonas, A. O., Selverian, D., Matthews, C. Z., Gutierrez, M., et al. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.020 · Cited by 27
Buse, J. B., Polonsky, K. S., & Burant, C. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00031-6 · Cited by 50
Self-citationExendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 29
Update on Safety Issues Related to Antihyperglycemic Therapy
Carpio, G., & Fonseca, V. A. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.92 · Cited by 33
Interpreting Adverse Signals in Diabetes Drug Development Programs
Bailey, C. J. (2013) · Diabetes Care · doi:10.2337/dc13-0182 · Cited by 30
Do we have enough data to confirm the link between antidiabetic drug use and cancer development?
Drzewoski, J., Drozdowska, A., & Śliwińska, A. (2011) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1029 · Cited by 28
Tokuyama, H., Kawamura, H., Fujimoto, M., Kobayashi, K., Nieda, M., Okazawa, T., Takemoto, M., & Shimada, F. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.03.034 · Cited by 24
Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
Elgart, J. F., Caporale, J., González, L., Aiello, E., Waschbusch, M., & Gagliardino, J. J. (2013) · Health Economics Review · doi:10.1186/2191-1991-3-11 · Cited by 27
Diabetes mellitus: Exploring the challenges in the drug development process
Patnaik, A., & Vaz, J. A. (2012) · Perspectives in Clinical Research · doi:10.4103/2229-3485.100660 · Cited by 26
Synthesis and biological evaluation of thiazole derivatives as GPR119 agonists
Kim, H., Cho, S. J., Yoo, M., Kang, S. K., Kim, K. R., Lee, H. H., Song, J. S., Rhee, S. D., Jung, W. H., Ahn, J. H., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.046 · Cited by 23
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 33
Sportiello, L., Rafaniello, C., Scavone, C., Vitale, C., Rossi, F., & Capuano, A. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.002 · Cited by 27
Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
Edwards, K. L., & Minze, M. G. (2015) · Core evidence · doi:10.2147/ce.s55944 · Cited by 24
Bernardo, B. C., Yildiz, G. S., Kiriazis, H., Harmawan, C. A., Tai, C. M. K., Ritchie, R. H., & McMullen, J. R. (2022) · Cells · doi:10.3390/cells11193117 · Cited by 26
The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders
Yang, J., Chen, W., & Chen, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091861 · Cited by 25
Incretin-Based Therapy and the Quest for Sustained Improvements in β-Cell Health
Drucker, D. J. (2011) · Diabetes Care · doi:10.2337/dc11-0986 · Cited by 22
Self-citationBioactive spermidine nanoparticles for effective cardiovascular recovery and diabetic therapy
Nie, T., Fang, Z., Liu, H., Zhang, X., Fang, Y., Xu, X., Huang, H. W., & Wu, J. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137353 · Cited by 21
Yang, Z., Fang, Y., Pham, T.-A. N., Lee, J., & Park, H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.12.011 · Cited by 21
Probable linagliptin-induced liver toxicity: A case report
Kutoh, E. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.009 · Cited by 21
Fiorentino, T. V., Owston, M. A., ABRAHAMIAN, G. A., Rosa, S. L., Marando, A., Perego, C., Cairano, E. S. D., Finzi, G., Capella, C., Sessa, F., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.09.009 · Cited by 21
Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders
Verma, M. K., Goel, R. N., Nandakumar, K., & Nemmani, K. V. S. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1487952 · Cited by 21
Aguerd, O., Elhrech, H., Fessikh, M. E., Goh, K. W., Omari, N. E., Aanniz, T., & Bouyahya, A. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106705 · Cited by 24
Valentine, W. J., Palmer, A. J., Lammert, M., Langer, J., & Brändle, M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.022 · Cited by 20
Saad, Z. A., Khodeer, D. M., Zaitone, S. A., Ahmed, A. A. M., & Moustafa, Y. M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117725 · Cited by 23
Practical combination therapy based on pathophysiology of type 2 diabetes
LEVIN, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s109216 · Cited by 21
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin
Flory, J., Small, D. S., Cassano, P. A., Brillon, D. J., Mushlin, A. I., & Hennessy, S. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.87 · Cited by 22
Yabe, D., & Seino, Y. (2011) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s5976 · Cited by 19
Pham, T.-A. N., Yang, Z., Fang, Y., Luo, J., Lee, J., & Park, H. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.12.013 · Cited by 19
‘Healthy’ individuals’ perceptions of type 1 and type 2 diabetes cause and management
Anderson-Lister, G., & Treharne, G. J. (2013) · Journal of Health Psychology · doi:10.1177/1359105313490315 · Cited by 19
Li, S., Wu, H., Han, D. H., Zhang, M., Li, N., Yu, W., Sun, D., Sun, Z., Ma, S., Gao, E., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6451902 · Cited by 19
Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors
Kim, K., & Jang, H.-J. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/171742 · Cited by 21
Cariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 19
Bele, S. D., Girada, S. B., Ray, A., Gupta, A., Oruganti, S., Babu, P. P., Rayalla, R. S., Kalivendi, S. V., Ibrahim, A., Puri, V., et al. (2020) · eLife · doi:10.7554/elife.52212 · Cited by 18
McShane, L. M., Franklin, Z. J., O'Harte, F. P. M., & Irwin, N. (2014) · Peptides · doi:10.1016/j.peptides.2014.08.002 · Cited by 19
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
Wroge, J., & Williams, N. T. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016663218 · Cited by 17
Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
Funch, D. P., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Li, L., Norman, H. S., Major‐Pedersen, A., Bosch‐Traberg, H., Gydesen, H., & Dore, D. D. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13739 · Cited by 17
Prescription Patterns of Novel Antihyperglycemic Medications
Ali, A. S., Khan, M., Ortega, D., Jaffery, S. H., Lamerato, L. E., & Budzynska, K. (2022) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2022.02.210360 · Cited by 16
Vidal, O. M., Velez, J. I., & Arcos‐Burgos, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-20343-z · Cited by 21
Hypoglycemia - Causes and Occurrences
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/864 · Cited by 17
Protection of pancreatic β-cells against glucotoxicity by short-term treatment with GLP-1
Park, S.-H., Park, J., Shim, H. M., Na, A., Bae, K.-C., Lim, J.-G., & Song, D. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.139 · Cited by 20
Singh, A., Gibert, Y., & Dwyer, K. M. (2018) · Pancreatology · doi:10.1016/j.pan.2018.06.006 · Cited by 17
Alogliptin benzoate for the treatment of type 2 diabetes
Seino, Y., & Yabe, D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.898750 · Cited by 15
An update on diagnosis and therapeutics for type-2 diabetes mellitus
Babu, S. (2023) · Bioinformation · doi:10.6026/97320630019295 · Cited by 16
Bhandari, M., Mathur, W., Kumar, R., Mishra, A., & Bhandari, M. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2770-y · Cited by 16
Optimization of a novel series of potent and orally bioavailable GPR119 agonists
Koshizawa, T., Morimoto, T., Watanabe, G., Watanabe, T., Yamasaki, N., Sawada, Y., Fukuda, T., Okuda, A., Shibuya, K., & Ohgiya, T. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.034 · Cited by 15
Protective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
Enhanced glycemic control with combination therapy for type 2 diabetes in primary care
Kuritzky, L., & Samraj, G. P. N. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0006-z · Cited by 20
Bile Acids in Pancreatic Carcinogenesis
Sharma, B., Twelker, K., Nguyen, C., Ellis, S., Bhatia, N. D., Kuschner, Z. D., Agriantonis, A., Agriantonis, G., Arnold, M., Dave, J., et al. (2024) · Metabolites · doi:10.3390/metabo14070348 · Cited by 17
Jacob, L., Waehlert, L., & Kostev, K. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815607860 · Cited by 15
Kato, K., Suzuki, K., Aoki, C., Sagara, M., Niitani, T., Wakamatsu, S., Yanagi, K., & Aso, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1317748 · Cited by 14
Incretin‐based drugs and risk of lung cancer among individuals with type 2 diabetes
Rouette, J., Yin, H., Yu, O. H. Y., Bouganim, N., Platt, R. W., & Azoulay, L. (2020) · Diabetic Medicine · doi:10.1111/dme.14287 · Cited by 16
Weight Management in Type 2 Diabetes Mellitus
Siram, A. T., Yanagisawa, R. T., & Skamagas, M. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20208 · Cited by 18
Kerr, B. D., Flatt, P. R., & Gault, V. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.021 · Cited by 15
Szkudelski, T., & Szkudelska, K. (2014) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-014-0371-y · Cited by 15
Lynch, M., Ahern, T., Timoney, I., Sweeney, C. M., Kelly, G., Hughes, R., Tobin, A., O'Shea, D. B., & Kirby, B. (2016) · Trials · doi:10.1186/s13063-016-1157-z · Cited by 15
Lee, S.-H., Ko, H. M., Jee, W., Kim, H., Chung, W., & Jang, H.-J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043682 · Cited by 17
Optische Kontrolle der Insulinsekretion mit einem Inkretinschalter
Broichhagen, J., Podewin, T., Meyer‐Berg, H., von Ohlen, Y., Johnston, N. R., Jones, B. J., Bloom, S. R., Rutter, G. A., Hoffmann‐Röder, A., Hodson, D. J., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201506384 · Cited by 13
de‐Madaria, E., Abad-González, Á. L., Aparicio, J. R., Aparisi, L., Boadas, J., Boix, E., Heras, G. D. L., Domínguez‐Muñoz, J. E., Farré, A., Fernández‐Cruz, L., et al. (2013) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2012.12.003 · Cited by 15
Avoiding hypoglycaemia: a new target of care for elderly diabetic patients
Wong, C. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj144494 · Cited by 15
Wang, T., Yang, J. Y., Buse, J. B., Pate, V., Tang, H., Barnes, E. L., Sandler, R. S., & Stürmer, T. (2019) · Diabetes Care · doi:10.2337/dc19-0162 · Cited by 13
Self-citationLi, B., Luo, Y. R., Zhang, Q., Fu, S., Chen, Y. D., Tian, J., & Guo, Y. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106854 · Cited by 14
Liatis, S., Papaoikonomou, S., GANOTOPOULOU, A., Papazafiropoulou, A. K., Dinos, C., Michail, M., Xilomenos, A., Melidonis, A. J., & Pappas, S. I. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-23 · Cited by 14
Umpierrez, G. E., & Meneghini, L. (2013) · Endocrine Practice · doi:10.4158/ep12292.ra · Cited by 12
Emerging Therapies for Nonalcoholic Fatty Liver Disease
Hameed, B., & Terrault, N. A. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.015 · Cited by 12
Fang, Y., Liu, X., Zhao, L., Wei, Z., Jiang, D., Shao, H., Zang, Y., Xu, J., Wang, Q., Liu, Y., et al. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.5.475 · Cited by 13
Lynch, M., Malara, A., Timoney, I., Vencken, S. F., Ahern, T., Awdeh, F., Sweeney, C. M., Galligan, M. C., Kelly, G., Hughes, R., et al. (2021) · Dermatology · doi:10.1159/000514494 · Cited by 12
Acute Liver Injury Induced by Sitagliptin: Report of Two Cases and Review of Literature
Shahbaz, A., Aziz, K., Umair, M., Sharifzadeh, M., & Sachmechi, I. (2018) · Cureus · doi:10.7759/cureus.2776 · Cited by 16
Insulin, Brain, Alzheimer’s Disease: New Evidence
Bulgakova, S. V., Иванович, Р. П., & Treneva, E. V. (2020) · Bulletin of Science and Practice · doi:10.33619/2414-2948/52/10 · Cited by 12
Kuwata, H., Tsujii, S., Fujita, N., Okamura, S., Iburi, T., Mashitani, T., Kitatani, M., Furuya, M., Hayashino, Y., & Ishii, H. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.2306 · Cited by 11
Lafferty, R. A., Tanday, N., Flatt, P. R., & Irwin, N. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154339 · Cited by 11
Development of Transdermal Delivery System of Vildagliptin and Its Comparison with Oral Therapy.
Nair, A. B., Kumria, R., Al‐Dhubiab, B. E., Attimarad, M., & Sreeharsha, N. (2016) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.50.1.17 · Cited by 11
Garber, A. J. (2011) · PubMed · Cited by 11
Haluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy
Hakim, M., Fathi, M. A., Abdulraziq, M., & Shehri, M. A. A. (2022) · Surgical Endoscopy · doi:10.1007/s00464-022-09294-8 · Cited by 11
Hwang, H., Lee, D., Son, J. D., Baek, J. G., Lee, H., Park, I., Kim, D. H., Lee, S. K., Kim, W. K., Kwon, H. C., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106466 · Cited by 10
Dasan, B., Rajamanickam, A., Munisankar, S., Menon, P. A., Ahamed, S. F., Nott, S., & Babu, S. (2023) · IJID Regions · doi:10.1016/j.ijregi.2023.08.009 · Cited by 12
DPP-4 inhibitors and atherosclerosis: The promise
Jialal, I., & Bajaj, M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.033 · Cited by 10
Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes
Sennik, D., Ahmed, F. W., & Russell-Jones, D. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.79 · Cited by 10
Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient
Dolan, R. D., Bazarbashi, A. N., Lo, A., & Smith, B. N. (2020) · ACG Case Reports Journal · doi:10.14309/crj.0000000000000380 · Cited by 10
Trakooncharoenvit, A., Hara, H., & Hira, T. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c01388 · Cited by 12
Parthan, G., Bhansali, S., Kurpad, A. V., Walia, R., Bhat, K., & Bhansali, A. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0228-z · Cited by 12
A new therapeutic class for the therapy of type 2 diabetes: DPP-4 inhibitors (sitagliptin)
Ábel, T., & Fehér, J. (2010) · Orvosi Hetilap · doi:10.1556/oh.2010.28910 · Cited by 9
Emerging glucose-lowering therapies: a guide for cardiologists
Gulsin, G. S., Graham-Brown, M. P. M., Davies, M. J., & McCann, G. P. (2019) · Heart · doi:10.1136/heartjnl-2019-315758 · Cited by 10
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care
STOLAR, M. W. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ec04e9 · Cited by 8
Postprandial Oxidative Stress and Gastrointestinal Hormones: Is There a Link?
Malínská, H., Kahleová, H., Topolčan, O., Vrzalová, J., Oliyarnyk, O., Kazdová, L., Belinova, L., Hill, M., & Pelikánová, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103565 · Cited by 11
Jain, S. V., & Ghate, M. D. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-0923-2 · Cited by 8
The Effect of Type-2 Diabetes on Cognitive Status and the Role of Anti-diabetes Medications
Alkasabera, A., Onyali, C. B., Anim-Koranteng, C., Shah, H. E., Ethirajulu, A., Bhawnani, N., & Mostafa, J. A. (2021) · Cureus · doi:10.7759/cureus.19176 · Cited by 8
Metadata
- Authors
- Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B.
- Affiliations
- University of Toronto (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Yale University (US)
- Park Nicollet Health Services (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-02-01
- Volume
- 33
- Issue
- 2
- Pages
- 428-433
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2809297
- OpenAlex
- W2134760433
- Cited by
- 316
- References
- 40
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 10 · 2023: 10 · 2022: 13 · 2021: 15 · 2020: 11 · 2019: 17 · 2018: 17 · 2017: 15 · 2016: 20 · 2015: 24 · 2014: 28 · 2013: 33 · 2012: 31
- FWCI
- 28.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- V Foundation for Cancer Research
- Park Nicollet Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Celgene
- F. Hoffmann-La Roche
- Exelixis
- Insulet Corporation
- MannKind Corporation
- ResMed
- Eisai
- Novo Nordisk
- Plexxikon
- National Institutes of Health
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007017)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, glycemic control, insulin resistance, insulin secretion, diabetes complications, drug safety, obesity
- MeSH terms
- Exenatide, Diabetes Mellitus, Type 2, Drug Administration Schedule, Humans, Hypoglycemic Agents, Peptides, Venoms, Incidence, Prevalence, Treatment Outcome, Risk Assessment, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.